NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06704724 2026-03-13A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.PfizerPhase 1 Active not recruiting30 enrolled
NCT06447662 2026-02-25A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.PfizerPhase 1 Recruiting330 enrolled
NCT03365882 2026-02-10S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by SurgerySWOG Cancer Research NetworkPhase 2 Completed240 enrolled 14 charts
NCT00556413 2026-02-05Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerInstitut du Cancer de Montpellier - Val d'AurellePhase 2 Completed42 enrolled
NCT04616183 2025-12-23LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal CancerM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting46 enrolled